Patents by Inventor Neil Bifulco

Neil Bifulco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK2 inhibitors
    Patent number: 11970498
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: April 30, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • INHIBITORS OF PROTEIN KINASE A
    Publication number: 20240132490
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.
    Type: Application
    Filed: February 1, 2022
    Publication date: April 25, 2024
    Applicant: Blueprint Medicines Corporation
    Inventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
  • CDK2 inhibitors
    Patent number: 11932648
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: March 19, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 INHIBITORS
    Publication number: 20230322791
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: February 8, 2023
    Publication date: October 12, 2023
    Inventors: Douglas Wilson, Neil Bifulco, JR., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 INHIBITORS
    Publication number: 20230159535
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 25, 2023
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20210347756
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: November 24, 2020
    Publication date: November 11, 2021
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 11059827
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 13, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 11046697
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: June 29, 2021
    Inventors: Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10875837
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20200109127
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 19, 2019
    Publication date: April 9, 2020
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK
    Publication number: 20190382410
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Application
    Filed: July 31, 2019
    Publication date: December 19, 2019
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20190359682
    Abstract: Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 28, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil BIFULCO, JR., Natasja BROOIJMANS, Brian L. HODOUS, Joseph L. KIM, Chandrasekhar V. MIDUTURU
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 10370379
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula I:
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 6, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Jr., Joseph L. Kim
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK
    Publication number: 20190169194
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
    Type: Application
    Filed: July 3, 2018
    Publication date: June 6, 2019
    Inventors: Steven Mark WENGLOWSKY, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, JR.
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10221154
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 5, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20180362613
    Abstract: Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
    Type: Application
    Filed: January 10, 2018
    Publication date: December 20, 2018
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: NEIL BIFULCO, JR., NATASJA BROOIJMANS, BRIAN L. HODOUS, JOSEPH L. KIM, CHANDRASEKHAR V. MIDUTURU
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 10017512
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 10, 2018
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10000490
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: June 19, 2018
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Chandrasekhar V. Miduturu
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20170253593
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 7, 2017
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Chandrasekhar V. Miduturu
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 9695165
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: July 4, 2017
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Chandrasekhar V. Miduturu